Cowen set a $50.00 target price on Supernus Pharmaceuticals (NASDAQ:SUPN) in a research report released on Wednesday, TipRanks reports. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.
Other equities analysts have also issued research reports about the stock. Cantor Fitzgerald set a $60.00 price objective on shares of Supernus Pharmaceuticals and gave the stock a buy rating in a report on Wednesday, May 8th. Stifel Nicolaus set a $55.00 price objective on shares of Supernus Pharmaceuticals and gave the stock a buy rating in a report on Wednesday. Mizuho reiterated a buy rating on shares of Supernus Pharmaceuticals in a report on Wednesday. Zacks Investment Research lowered shares of Supernus Pharmaceuticals from a buy rating to a hold rating in a report on Wednesday, July 17th. Finally, BidaskClub upgraded shares of Supernus Pharmaceuticals from a hold rating to a buy rating in a report on Wednesday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. Supernus Pharmaceuticals presently has an average rating of Buy and a consensus price target of $54.43.
SUPN stock traded down $0.27 during trading on Wednesday, reaching $28.39. The stock had a trading volume of 682,711 shares, compared to its average volume of 505,890. Supernus Pharmaceuticals has a 1-year low of $27.59 and a 1-year high of $51.38. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.72 and a quick ratio of 2.59. The firm has a market capitalization of $1.50 billion, a P/E ratio of 14.70, a P/E/G ratio of 0.97 and a beta of 1.54. The company has a fifty day moving average of $32.02.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Patriot Financial Group Insurance Agency LLC bought a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter worth about $33,000. Financial Gravity Wealth Inc. bought a new stake in shares of Supernus Pharmaceuticals in the 1st quarter worth about $44,000. Advisor Group Inc. increased its position in shares of Supernus Pharmaceuticals by 17.2% in the 4th quarter. Advisor Group Inc. now owns 2,082 shares of the specialty pharmaceutical company’s stock worth $69,000 after purchasing an additional 306 shares during the last quarter. Bremer Bank National Association bought a new stake in shares of Supernus Pharmaceuticals in the 1st quarter worth about $94,000. Finally, Huntington National Bank increased its position in shares of Supernus Pharmaceuticals by 881.4% in the 1st quarter. Huntington National Bank now owns 4,485 shares of the specialty pharmaceutical company’s stock worth $157,000 after purchasing an additional 4,028 shares during the last quarter. 99.29% of the stock is owned by institutional investors.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.
Featured Story: Economic Bubble
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.